| Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain S Soverini, C De Benedittis, K Machova Polakova, A Brouckova, D Horner, ... Blood, The Journal of the American Society of Hematology 122 (9), 1634-1648, 2013 | 184 | 2013 |
| Differences among young adults, adults and elderly chronic myeloid leukemia patients F Castagnetti, G Gugliotta, M Baccarani, M Breccia, G Specchia, L Levato, ... Annals of Oncology 26 (1), 185-192, 2015 | 104 | 2015 |
| The BCR‐ABL1 transcript type influences response and outcome in P hiladelphia chromosome‐positive chronic myeloid leukemia patients treated frontline with imatinib F Castagnetti, G Gugliotta, M Breccia, A Iurlo, L Levato, F Albano, ... American journal of hematology 92 (8), 797-805, 2017 | 103 | 2017 |
| Main changes in European clinical trials regulation (no 536/2014) E Tenti, G Simonetti, MT Bochicchio, G Martinelli Contemporary clinical trials communications 11, 99-101, 2018 | 52 | 2018 |
| Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia G Gugliotta, F Castagnetti, M Breccia, L Levato, M D’Adda, F Stagno, ... haematologica 100 (9), 1146, 2015 | 47 | 2015 |
| Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia M Arpinati, G Tolomelli, MT Bochicchio, F Castagnetti, M Amabile, ... Biology of Blood and Marrow Transplantation 19 (5), 735-740, 2013 | 31 | 2013 |
| Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes MY Follo, A Pellagatti, RN Armstrong, S Ratti, S Mongiorgi, S De Fanti, ... Leukemia 33 (9), 2276-2290, 2019 | 29 | 2019 |
| Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy S Luatti, C Baldazzi, G Marzocchi, G Ameli, MT Bochicchio, S Soverini, ... Oncotarget 8 (18), 29906, 2017 | 28 | 2017 |
| Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients F Castagnetti, M Breccia, G Gugliotta, B Martino, M D’Adda, F Stagno, ... haematologica 101 (10), 1200, 2016 | 25 | 2016 |
| Genetics and pathogenetic role of inflammasomes in Philadelphia negative chronic myeloproliferative neoplasms: a narrative review V Di Battista, MT Bochicchio, G Giordano, M Napolitano, A Lucchesi International Journal of Molecular Sciences 22 (2), 561, 2021 | 24 | 2021 |
| Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients E Zuffa, E Franchini, C Papayannidis, C Baldazzi, G Simonetti, N Testoni, ... Oncotarget 6 (31), 31284, 2015 | 23 | 2015 |
| Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations G Simonetti, C Mengucci, A Padella, E Fonzi, G Picone, C Delpino, ... Leukemia 35 (10), 2813-2826, 2021 | 19 | 2021 |
| Kevetrin induces apoptosis in TP53 wild‑type and mutant acute myeloid leukemia cells R Napolitano, S De Matteis, S Carloni, S Bruno, G Abbati, L Capelli, ... Oncology reports 44 (4), 1561-1573, 2020 | 14 | 2020 |
| Droplet Digital PCR for BCR–ABL1 Monitoring in Diagnostic Routine: Ready to Start? MT Bochicchio, J Petiti, P Berchialla, B Izzo, E Giugliano, E Ottaviani, ... Cancers 13 (21), 5470, 2021 | 13 | 2021 |
| Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology Z Eran, M Zingariello, MT Bochicchio, C Bardelli, AR Migliaccio F1000Research 8, 2019 | 13 | 2019 |
| Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells A Ghelli Luserna Di Rorà, M Ghetti, L Ledda, A Ferrari, M Bocconcelli, ... Cell Biology and Toxicology, 1-17, 2021 | 12 | 2021 |
| Validation of the new European LeukemiaNet (ELN) recommendations for Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia: an analysis of the GIMEMA CML Working … S Soverini, A Gnani, C De Benedittis, F Castagnetti, G Gugliotta, ... Blood, The Journal of the American Society of Hematology 118 (21), 112-112, 2011 | 12 | 2011 |
| GIMEMA CML Working Party. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline … F Castagnetti, G Gugliotta, M Breccia, A Iurlo, L Levato, F Albano, ... Am J Hematol 92 (8), 797-805, 2017 | 9 | 2017 |
| Five-year results of nilotinib 400 mg BID in early chronic phase chronic myeloid leukemia (CML): high rate of deep molecular response-update of the GIMEMA CML WP Trial CML0307 G Rosti, G Gugliotta, F Castagnetti, M Breccia, L Levato, G Rege-Cambrin, ... Blood 120 (21), 3784, 2012 | 8 | 2012 |
| Gimema ALL2418: interim analysis of a phase Iia study of feasibility and effectiveness of Inotuzumab Ozogamicin in adult patients with B-Cell Acute Lymphoblastic Leukemia with … G Marconi, A Piciocchi, S Chiaretti, C Papayannidis, M Lunghi, P Salutari, ... Blood 140 (Supplement 1), 6119-6121, 2022 | 6 | 2022 |
